Advanced Therapeutics in Rheumatoid Arthritis (RA)
Who is this study for? Adults with rheumatoid arthritis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• patients with RA who meet criteria for obtaining an advanced therapeutic through usual care
• active RA with 5 or more swollen joints
• seropositive
• presence of erosions
• failure of methotrexate and hydroxychloroquine and sulfasalazine
• failure of Leflunomide
⁃ \> or equal to 18 years
• able to provide consent
• able to attend usual follow up visits
Locations
Other Locations
Canada
Rheumatology Clinic, St. Joseph's Health Care
RECRUITING
London
Contact Information
Primary
Janet E Pope, MD MPH
janet.pope@sjhc.london.on.ca
519 646-6000
Time Frame
Start Date: 2020-03-01
Estimated Completion Date: 2025-03
Participants
Target number of participants: 144
Treatments
Active_comparator: etanercept
etanercept 50 mg subcutaneously injected per week
Active_comparator: tofacitinib
tofacitinib 5 mg orally daily
Related Therapeutic Areas
Sponsors
Collaborators: Academic Medical Organization of Southwestern Ontario
Leads: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's